Patients taking Genentech Inc.’s recently approved breast cancer therapy Perjeta lived longer when taking the drug in combination with he Genentech blockbuster Herceptin and docetaxel chemotherapy.
Patients who took combination including Perjeta, also known as pertuzumab, had a 38 percent reduced risk of HER2-positive metastatic breast cancer worsening or of them dying, compared to patients who were given only Herceptin and docetaxel.
Median progression-free survival -- or the length of time during and after treatment when a cancer does not worsen -- was 18.5 months for those taxing Perjeta, compared to 12.4 months for the group without Perjeta.
No comments:
Post a Comment